Rein Therapeutics Inc.
Rein Therapeutics Inc. (RNTX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
rntx · stock forecast · 2 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 2 Wall Street analysts in the past 3 months
Buy
2 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$6.00
Consensus
$6.00
+532.4% upside
Low
$6.00
Median: $6 · Last Close: $0.95
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.90 | ↓ 4.88% |
1-day model range: $0.89–$0.92. Peak: $0.92 (-4.88%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $0 | -50.0% |
| 2028 | $0 | -62.5% |
| 2029 | $0 | -67.2% |
| 2030 | $0 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · RNTX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-01-21 | Brookline Capital | Downgrade ↓ | Buy→Hold |
| 2025-08-19 | Brookline Capital | Downgrade ↓ | Buy→Hold |
Wall Street analysts have recently issued updated ratings on Rein Therapeutics Inc. (RNTX) stock. Of the recent 3 rating actions, 0 were upgrades and 2 were downgrades. 2 analysts currently cover RNTX.
Analyst Recommendation Trends
RNTX analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$70M
Revenue Next Year
$128M
↑ 83.0% YoY
EPS This Year
$-0.53
EPS Next Year
$-0.50
↓ 5.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast RNTX EPS of $-0.53 for the current fiscal year, based on estimates from 1 analysts. The RNTX revenue forecast is $70M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The RNTX stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RNTX price target is $6.00 (+532.4% upside), with an analyst consensus of Buy.
The RNTX short-term stock prediction for tomorrow is $0.90 (-4.88%). The RNTX stock price prediction for 2027 estimates an average of $0. The RNTX stock prediction for 2030 projects a range of $0–$0.
Rein Therapeutics Inc. trades on NASDAQ under the ticker RNTX. The RNTX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
RNTX forecast · 8 questionsAccording to 2 Wall Street analysts, the average 12-month RNTX price target is $6.00, with a high forecast of $6.00 and a low of $6.00. The median price target is shown in the chart above when available. This implies +532.4% potential upside from the current price of $0.95.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.